Calibration of HIV-1 working reagents for nucleic acid amplification techniques against the 1st international standard for HIV-1 RNA

被引:26
作者
Davis, C
Heath, A
Best, S
Hewlett, I
Lelie, N
Schuurman, R
Holmes, H
机构
[1] Natl Inst Biol Stand & Controls, Div Retrovirol, Potters Bar EN6 3QG, Herts, England
[2] Natl Inst Biol Stand & Controls, Div Informat, Potters Bar EN6 3QG, Herts, England
[3] Natl Serol Reference Lab, Fitzroy, Vic 3065, Australia
[4] Food & Drug Adm, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA
[5] Sanquin CLB Diagnost Div, VQC Lab, NL-1867 CT Alkmaar, Netherlands
[6] Univ Utrecht Hosp, Dept Virol, NL-3584 CX Utrecht, Netherlands
关键词
HIV-1; RNA; NAT; calibration; working reagents; International Standard;
D O I
10.1016/S0166-0934(02)00187-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Many laboratories use working reagents/run controls to monitor the performance of their nucleic acid amplification techniques (NAT) for the measurement of HIV-1 RNA. A collaborative study was carried out in order to calibrate seven internationally available working reagents, QC105 (National Serology Reference Laboratory [NRL], Australia), B5 and B10 (Center for Biological Evaluation and Research [CBER], USA), Pelispy (Central Laboratory of the Netherlands Blood Transfusion Service [CLB], The Netherlands), PWS-1 and PWS-3 (National Institute for Biological Standards and Control [NIBSC], UK) and IRC (Virology Networks [VN], The Netherlands) against the 1st International Standard for HIV-1 RNA (code 97/656). Twenty-one laboratories from 12 different countries participated in the collaborative study and from the results it was determined that QC105 contained 4.0 log(10) International Units (IU)/ml, B5 2.2 log(10) IU/ml, B10 3.8 log(10) IU/ml, Pelispy 4.4 log(10) IU/ml, PWS-1 3.6 log(10) IU/ml, PWS-3 2.7 log(10) IU/ml and IRC 4.3 log(10) IU/ml. The seven working reagents calibrated in this international study may be used to validate and standardise the large number of qualitative and quantitative, commercial and in-house NAT assays that are currently being applied in the fields of blood safety and patient management. They will also help laboratories to comply with the sensitivity requirements that may be brought in by the regulatory authorities and may contribute to further harmonisation of guidelines on NAT published by organisations such as the European Medicines Evaluation Agency (EMEA), Paul-Ehrlich Institute and CBER, FDA. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:37 / 44
页数:8
相关论文
共 12 条
[1]  
Center for Drug Evaluation and Research (CDER) Food and Drug Administration of the United States (US-FDA), 2002, GUID IND
[2]   Comparison of three commercial assays for the quantification of plasma HIV-1 RNA from individuals with low viral loads [J].
Chew, CB ;
Zheng, F ;
Byth, K ;
Van Asten, M ;
Workman, C ;
Dwyer, DE .
AIDS, 1999, 13 (14) :1977-1978
[3]  
Collet D, 1991, MODELLING BINARY DAT
[4]   Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection [J].
Coombs, RW ;
Welles, SL ;
Hooper, C ;
Reichelderfer, PS ;
DAquila, RT ;
Japour, AJ ;
Johnson, VA ;
Kuritzkes, DR ;
Richman, DD ;
Kwok, S ;
Todd, J ;
Jackson, JB ;
DeGruttola, V ;
Crumpacker, CS ;
Kahn, J .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) :704-712
[5]   An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques [J].
Holmes, H ;
Davis, G ;
Heath, A ;
Hewlett, I ;
Lelie, N .
JOURNAL OF VIROLOGICAL METHODS, 2001, 92 (02) :141-150
[6]   New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes [J].
Janssen, RS ;
Satten, GA ;
Stramer, SL ;
Rawal, BD ;
O'Brien, TR ;
Weiblen, BJ ;
Hecht, FM ;
Jack, N ;
Cleghorn, FR ;
Kahn, JO ;
Chesney, MA ;
Busch, MP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :42-48
[7]  
LOWER J, 2001, BUNDESANZEIGER
[8]   Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission [J].
Murthy, KK ;
Henrard, DR ;
Eichberg, JW ;
Cobb, KE ;
Busch, MP ;
Allain, JP ;
Alter, HJ .
TRANSFUSION, 1999, 39 (07) :688-693
[9]  
Roth WK, 2000, VOX SANG, V78, P257
[10]   The risk of transfusion-transmitted viral infections [J].
Schreiber, GB ;
Busch, MP ;
Kleinman, SH ;
Korelitz, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1685-1690